Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21751] to p73 (phospho Y99)
- Suitable for: Dot blot, WB, IP
- Reacts with: Human
Product nameAnti-p73 (phospho Y99) antibody [EPR21751]
See all p73 primary antibodies
DescriptionRabbit monoclonal [EPR21751] to p73 (phospho Y99)
Tested applicationsSuitable for: Dot blot, WB, IPmore details
Species reactivityReacts with: Human
Synthetic peptide within Human p73 aa 50-150 (phospho Y99). The exact sequence is proprietary.
Database link: O15350
- WB: HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate. IP: HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab218625 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 80 kDa (predicted molecular weight: 69 kDa).|
FunctionParticipates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.
Tissue specificityExpressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue.
Sequence similaritiesBelongs to the p53 family.
Contains 1 SAM (sterile alpha motif) domain.
DomainPossesses an acidic transactivation domain, a central DNA binding domain and a C-terminal oligomerization domain that binds to the ABL tyrosine kinase SH3 domain.
The WW-binding motif mediates interaction with WWOX.
modificationsIsoform alpha (but not isoform beta) is sumoylated on Lys-627, which potentiates proteasomal degradation but does not affect transcriptional activity.
Higher levels of phosphorylation seen in the brain from patients with Huntington disease.
Ubiquitinated; leading to its degradation by the proteasome.
Cellular localizationNucleus. Accumulates in the nucleus in response to DNA damage.
- Information by UniProt
- p53 like transcription factor antibody
- p53 related protein antibody
- p53-like transcription factor antibody
All lanes : Anti-p73 (phospho Y99) antibody [EPR21751] (ab218625) at 1/1000 dilution
Lane 1 : Untreated HT-1376 (human urinary bladder carcinoma cell line) whole cell lysate
Lane 2 : HT-1376 treated with 1 mM pervanadate for 30 minutes, whole cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 69 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted?
Exposure time: 15 seconds
Blocking/Dilution buffer: 5% NFDM/TBST.
The molecular mass observed is consistent with the literature (PMID:11466610).
p73 (phospho Y99) was immunoprecipitated from 0.35 mg of HT-1376 (human urinary bladder carcinoma cell line) treated with 1mM Pervanadate for 30 min whole cell lysate with ab218625 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab218625 at 1/2000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1/10000 dilution.
Lane 1: HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate 10 μg (input).
Lane 2: ab218625 IP in HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab218625 in HT-1376 treated with 1mM Pervanadate for 30 min whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 seconds.
Dot blot analysis of p73 (phospho Y99) with ab218625 at 1/1000 dilution.
Lane 1: p73 (phospho Y99) peptide.
Lane 2: p73 non-phospho peptide.
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution was used as secondary antibody.
Blocking/Dilution buffer: 5% NFDM/TBST.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab218625 has not yet been referenced specifically in any publications.